What Can Investors Expect from Innate Pharma's(NASDAQ:IPHA) Pipeline Progress and Q3 2026 Financial Update?

Sonal Goyal

05 November 2026 07:54 PM AEDT

What Can Investors Expect from Innate Pharma's(NASDAQ:IPHA) Pipeline Progress and Q3 2026 Financial Update?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 will be presented at ENA 2026 on November 18, with 76 patients enrolled across multiple solid tumor types.

• Lacutamab Phase 3 TELLOMAK-3 trial is on track for first patient dosing in Q1 2027, with an FDA Accelerated Approval filing planned for H2 2027.

• AstraZeneca-led PACIFIC-9 Phase 3 trial readout involving monalizumab is expected in H1 2027.

• Cash position stood at EUR 96.8 million as of September 30, 2026, providing anticipated runway until end of Q1 2028.

Innate Pharma SA(NASDAQ:IPHA), a French clinical-stage biopharmaceutical company focused on immuno-oncology, has released its third quarter 2026 Business and financial update on November 5, 2026. The company is advancing multiple clinical programs across its pipeline, with several data readouts and regulatory milestones expected over the coming quarters.

IPH4502: Nectin-4 ADC Approaching Data Disclosure

The most near-term catalyst for Innate Pharma is the upcoming presentation of Phase 1 dose-escalation data for IPH4502, the company's proprietary Nectin-4-targeting antibody-drug conjugate. IPH4502 combines a differentiated antibody with a proprietary stable linker and an exatecan payload, designed to potentially overcome resistance to Enfortumab Vedotin in urothelial carcinoma and target tumors with low or heterogeneous Nectin-4 expression.

Enrollment in the Phase 1 dose-escalation of the IPH4502-101 study has been completed, with 76 patients enrolled across multiple solid tumor types. The data will be presented as a poster at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics on November 18, 2026, in Barcelona. Following the ENA presentation, Innate Pharma will host a hybrid event focused on IPH4502 on November 18 with both in-person attendance in London and a live webcast.

Lacutamab: Strategic Partnership With Sobi Advances

Innate Pharma's anti-KIR3DL2 antibody lacutamab is progressing toward a Phase 3 trial following the strategic partnership with Sobi announced in August 2026. The confirmatory Phase 3 TELLOMAK-3 study in Cutaneous T Cell Lymphoma (CTCL) is expected to begin dosing patients in Q1 2027.

The TELLOMAK-3 program includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides. Innate Pharma plans an FDA filing in H2 2027 for accelerated approval in Sézary syndrome based on existing Phase 2 TELLOMAK data, provided the confirmatory Phase 3 study is underway. The Sobi partnership provides resources and commercial capabilities to support the development and potential commercialization of lacutamab.

Monalizumab and AstraZeneca Collaboration

The AstraZeneca-led PACIFIC-9 Phase 3 trial, evaluating durvalumab in combination with monalizumab or oleclumab in unresectable Stage III non-small cell lung cancer (NSCLC), has completed enrollment. The readout is now expected in the first half of 2027. Innate Pharma retains Royalty and milestone interests in monalizumab through its collaboration with AstraZeneca.

Financial Position and Cash Runway

Innate Pharma reported a cash position of EUR 96.8 million as of September 30, 2026, which includes short-term investments of EUR 20.6 million and non-current financial instruments of EUR 6.0 million. The company anticipates this provides cash runway until the end of Q1 2028, covering the key data readouts and regulatory milestones planned across its pipeline.

CEO Jonathan Dickinson noted that the company's improved cash position enables it to execute on its strategic priorities, including the IPH4502 data presentation and preparation for the Phase 3 TELLOMAK-3 study.

The Road Ahead

Innate Pharma enters a period of concentrated catalysts, with IPH4502 dose-escalation data at ENA on November 18, lacutamab Phase 3 initiation targeted for Q1 2027, and the PACIFIC-9 readout expected in H1 2027. The company's ability to advance multiple programs simultaneously while maintaining runway into early 2028 reflects the financial support provided by the Sobi partnership and existing cash resources.

FAQs

Q: When will IPH4502 data be presented?

A: Phase 1 dose-escalation data for IPH4502 will be presented at the ENA 2026 Symposium on November 18, 2026, in Barcelona.

Q: What is Innate Pharma's cash position?

A: The company reported a cash position of EUR 96.8 million as of September 30, 2026, providing anticipated runway until the end of Q1 2028.

Q: What is the TELLOMAK-3 trial?

A: TELLOMAK-3 is a confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma, including cohorts for Sézary syndrome and Mycosis Fungoides, being developed in collaboration with Sobi.

Q: When is the PACIFIC-9 trial readout expected?

A: The AstraZeneca-led PACIFIC-9 Phase 3 trial readout is expected in the first half of 2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.